ALS Tracker

← All drugs

In development

AP-101

Bottom line

One small placebo-controlled trial showed it is safe but did not slow decline in function overall. Hints of longer survival and of benefit in subgroups come from exploratory analyses that only the planned Phase 3 can confirm.

AP-101 is a lab-made human antibody, given by IV drip every three weeks, that seeks out and clears misfolded SOD1 protein, a toxic form found in SOD1-ALS and possibly in many people with sporadic ALS. A Phase 2 trial in 73 people met its main goal, which was safety. It did not slow decline on the ALS functional score in the main sporadic ALS group; exploratory analyses hinted at longer survival and slower decline in some subgroups, but these are company-reported and not yet in a peer-reviewed journal. The company plans a roughly 300-person Phase 3 trial starting in 2027.

Information checked 5 Nov 2026

Evidence: Hints only

Studies: 1 mixed

Controlled trials missed their main goal. Some measures or subgroups looked better, which needs confirming.

How we decide the overall verdict: How to read this site.

At a glance

CompanyAL-S PharmaExplanation and sources

AL-S Pharma is a small private Swiss biotech near Zurich that develops only AP-101. It is co-owned by Neurimmune, which discovered the antibody, and the investor TVM Capital Life Science. It appointed a new chief executive, Harry Welten, in October 2026.

Sources

  1. AP-101AL-S Pharma · Company website
  2. AL-S Pharma Appoints Harry Welten as Chief Executive OfficerAL-S Pharma · 14 Oct 2026 · Company press release
How it worksAntibody that clears toxic misfolded SOD1 proteinMisfolded SOD1Explanation and sources

SOD1 is a normal protein, but when it folds the wrong way it becomes toxic to motor neurons and can spread from cell to cell. AP-101 is designed to bind and remove only the misfolded form, leaving normal, protective SOD1 alone rather than lowering all SOD1. The idea is that this could help both SOD1-ALS and the sporadic ALS cases where misfolded SOD1 is also found.

Sources

  1. AP-101AL-S Pharma · Company website
  2. AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of ALSAL-S Pharma · 4 Sept 2025 · Company press release
StagePhase 2Phase 2 done; Phase 3 planned to start in 2027Explanation and sources

The Phase 2 trial (AP-101-02) is complete. In October 2026 the company described a Phase 3 trial, AP101-03, of about 300 people given AP-101 or placebo for 12 months, run with the NEALS network. It now expects to start that trial in 2027, later than the "end of 2026" target it gave in March 2026.

Sources

  1. AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual MeetingAL-S Pharma · 26 Oct 2026 · Company press release
  2. Study of AP-101 in Sporadic and SOD1-ALS (NCT05039099)ClinicalTrials.gov · Trial registry
  3. Additional Phase 2 Data of AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALSAL-S Pharma · 19 Mar 2026 · Company press release
Best reported effectNo slowing of function overall; survival hints onlyTime to death or permanent ventilation (exploratory)Explanation and sources

The trial's main goal was safety, which it met. During the 24-week placebo-controlled period, the ALS functional score (ALSFRS-R) did not differ from placebo in the main sporadic ALS group. In exploratory analyses, people who started AP-101 straight away did better on a combined death-or-ventilation measure than people who switched from placebo to AP-101 after 24 weeks (sporadic ALS p=0.013; SOD1-ALS p=0.036). Slower ALSFRS-R decline was seen only in SOD1 carriers, where the groups were not evenly matched at the start, and in people with high misfolded SOD1. These are company-reported results, not yet in a peer-reviewed journal.

This is the most favourable result reported. See all key studies for the full picture.

Sources

  1. AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of ALSAL-S Pharma · 4 Sept 2025 · Company press release
  2. AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101, Supporting Plans for a Confirmatory Phase 3 StudyAL-S Pharma · 5 Dec 2025 · Company press release
  3. AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual MeetingAL-S Pharma · 26 Oct 2026 · Company press release
  4. AD/PD 2026: AL-S Pharma's AP-101 data backs approach to target misfolded SOD1 in ALSClinical Trials Arena (GlobalData) · 24 Mar 2026 · News
Who it's forSporadic ALS and SOD1-ALSSporadic, SOD1 · IV infusion every 3 weeksExplanation and sources

Phase 2 included 52 people with sporadic ALS and 21 with SOD1-ALS. The company says the strongest signals were in SOD1 carriers and in people with high levels of misfolded SOD1, which it hopes to measure to pick patients in future.

Sources

  1. AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of ALSAL-S Pharma · 4 Sept 2025 · Company press release
  2. AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026AL-S Pharma · 24 Jun 2026 · Company press release
What's nextStart of the ~300-person Phase 3 trial AP101-03Expected 2027Explanation and sources

The company says the Phase 3 trial will test 2,500 mg of AP-101 by IV every three weeks against placebo for 12 months. It gave 2027 as the start year; the exact sites and month have not been announced.

Sources

  1. AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual MeetingAL-S Pharma · 26 Oct 2026 · Company press release
  2. Evotec fills CSO vacancy, Sibylla and AL-S Pharma name new CEOsEuropean Biotechnology · News
Can I join?No trial recruiting now; Phase 3 expected in 2027Explanation and sources

The Phase 2 trial has finished and no trial is currently enrolling. We found no announced expanded access programme. Watch for site lists when the Phase 3 trial opens.

Sources

  1. Study of AP-101 in Sporadic and SOD1-ALS (NCT05039099)ClinicalTrials.gov · Trial registry
  2. AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual MeetingAL-S Pharma · 26 Oct 2026 · Company press release

Signal: Active

Signal measures how often, and how reliably, AL-S Pharma tells the public about this drug. It says nothing about whether the drug works. A quiet company isn't necessarily a bad sign, but regular, on-time updates help patients plan.

Last company update26 Oct 2026 (10 days ago)40 / 40
Company updates in the last 12 months635 / 35
Promises kept1 of 2 on time13 / 25
Signal score88 / 100 · Active

Announced milestones

70 or more is Active, 45 or more is Steady, 20 or more is Quiet, below 20 is Silent. Full method.

Timeline

10 events, newest first. Company updates are marked; independent news and regulator decisions are shown too.

2026

  1. ConferenceNEALS

    AP-101 presented at the NEALS 2026 annual meeting

    AP-101 Phase 2 results and Phase 3 plans were on the agenda of the NEALS annual meeting, the North American ALS clinical trial network that will help run Phase 3.

  2. Press releaseFrom the companyAL-S Pharma

    Weight data and Phase 3 design shared ahead of NEALS meeting

    In post-hoc analyses, people on AP-101 lost less weight, most clearly in SOD1 carriers. The planned Phase 3, AP101-03, would treat about 300 people for 12 months versus placebo.

  3. Press releaseFrom the companyAL-S Pharma

    New CEO named; Phase 3 start now expected in 2027

    Harry Welten replaced Michael Salzmann as chief executive. The company now expects Phase 3 to begin in 2027.

  4. Press releaseFrom the companyAL-S Pharma

    Phase 2 data presented at ENCALS 2026

    At the European ALS meeting, the company presented data it says support misfolded SOD1 as a treatment target, with stronger effects in people with high misfolded SOD1.

  5. Press releaseFrom the companyAL-S Pharma

    More Phase 2 data at AD/PD; Phase 3 targeted for end of 2026

    New analyses were presented at the AD/PD conference, and the company said it aimed to start Phase 3 by the end of 2026.

  6. Investor updateFrom the companyAL-S Pharma

    Company to present Phase 2 results at J.P. Morgan conference

    AL-S Pharma announced its CEO and chief medical officer would present the AP-101 Phase 2 results at the J.P. Morgan Healthcare Conference on 15 January 2026.

2025

  1. Press releaseFrom the companyAL-S Pharma

    Full Phase 2 results presented at the ALS/MND symposium

    Detailed results were shown at the International Symposium on ALS/MND, and the company said they support a confirmatory Phase 3 trial.

  2. Press releaseFrom the companyAL-S Pharma (via PR Newswire)

    ALS trial expert Angela Genge becomes chief medical officer

    The company hired Montreal neurologist Angela Genge to lead clinical development as it prepares for Phase 3.

  3. Press releaseFrom the companyAL-S Pharma

    Positive topline Phase 2 results announced

    AL-S Pharma said AP-101 met its main safety goal and showed signals of slower decline and longer survival in exploratory analyses, including in sporadic ALS.

  4. Trial registryClinicalTrials.gov

    Phase 2 trial reaches primary completion

    The registry lists this as the date the last participant completed the main part of the AP-101-02 trial, which enrolled 73 people with sporadic or SOD1-ALS.

All sources for this page

  1. AL-S Pharma Announces Positive Topline Results from Phase 2 Study of AP-101 for the Treatment of ALSAL-S Pharma · 4 Sept 2025 · Company press release
  2. AL-S Pharma Appoints Prof. Dr. Angela Genge as Chief Medical OfficerAL-S Pharma (via PR Newswire) · 25 Sept 2025 · Company press release
  3. AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101, Supporting Plans for a Confirmatory Phase 3 StudyAL-S Pharma · 5 Dec 2025 · Company press release
  4. AL-S Pharma newsAL-S Pharma · Company website
  5. Additional Phase 2 Data of AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALSAL-S Pharma · 19 Mar 2026 · Company press release
  6. AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026AL-S Pharma · 24 Jun 2026 · Company press release
  7. AL-S Pharma Appoints Harry Welten as Chief Executive OfficerAL-S Pharma · 14 Oct 2026 · Company press release
  8. AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual MeetingAL-S Pharma · 26 Oct 2026 · Company press release
  9. AP-101AL-S Pharma · Company website
  10. Study of AP-101 in Sporadic and SOD1-ALS (NCT05039099)ClinicalTrials.gov · Trial registry
  11. NEALS 2026 Annual Meeting agendaNEALS · Conference presentation
  12. AP-101 holds promise for ALS, topline data showALS News Today · News
  13. AD/PD 2026: AL-S Pharma's AP-101 data backs approach to target misfolded SOD1 in ALSClinical Trials Arena (GlobalData) · 24 Mar 2026 · News
  14. Evotec fills CSO vacancy, Sibylla and AL-S Pharma name new CEOsEuropean Biotechnology · News